glp-1 dual agonist Tirzepatide, a GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction | Cardiovascular Diabetology GIPR/GLP-1R dual agonist therapies for

The author or authors do not own shares in any securities mentioned in this article

Postponing GLP-1 RAs before endoscopic intervention or surgery may hinder diabetes management and increase cancellation rates without significant advantages

Adipocyte-derived lipids mediate melanoma progression via FATP proteins

1) S-850S-851 (2012)

[DOI] [PMC free article] [PubMed] [Google Scholar] 38.Astrup A., Rssner S., Van Gaal L., Rissanen A., Niskanen L., Al Hakim M., Madsen J., Rasmussen M.F., Lean M.E., NN8022-1807 Study Group Effects of liraglutide in the treatment of obesity: A randomised, double-blind, placebo-controlled study

On the other hand, GLP-1 suppresses glucagon secretion from pancreatic -cells [26]